Austar Lifesciences Limited (6118.HK)
- Previous Close
0.730 - Open
0.730 - Bid 0.700 x --
- Ask 0.730 x --
- Day's Range
0.700 - 0.730 - 52 Week Range
0.450 - 1.100 - Volume
58,000 - Avg. Volume
54,879 - Market Cap (intraday)
358.807M - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
23.33 - EPS (TTM)
0.030 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 19, 2015
- 1y Target Est
--
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions. In addition, the company provides pharmaceutical process contamination control; packaging and aseptic containment; biosafety and lab animal equipment and consumables, as well as offers powder and solid equipment; freeze-dryer, sterile filling and visual inspection equipment. Further, it offers project management and process engineering; engineering design and consulting services; operation and maintenance of facility management systems. Additionally, the company provides lifecycle digital solutions and professional consulting services. Austar Lifesciences Limited was founded in 1991 and is headquartered in Shanghai, China.
www.austar.com.hkRecent News: 6118.HK
View MorePerformance Overview: 6118.HK
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6118.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6118.HK
View MoreValuation Measures
Market Cap
374.18M
Enterprise Value
628.19M
Trailing P/E
22.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.23
Price/Book (mrq)
0.44
Enterprise Value/Revenue
0.39
Enterprise Value/EBITDA
6.33
Financial Highlights
Profitability and Income Statement
Profit Margin
1.07%
Return on Assets (ttm)
1.02%
Return on Equity (ttm)
1.73%
Revenue (ttm)
1.5B
Net Income Avi to Common (ttm)
16.08M
Diluted EPS (ttm)
0.030
Balance Sheet and Cash Flow
Total Cash (mrq)
167.8M
Total Debt/Equity (mrq)
50.66%
Levered Free Cash Flow (ttm)
56.33M